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University Medical Center, Maastricht, The Netherlands.BACKGROUND Approximately one-third of the patients with heart
failure (HF) treated with cardiac resynchronization therapy (CRT)
fail to respond. Positioning the left ventricular (LV) pacing lead in
the area of the latest electrical delay may improve the response to
CRT. Multipoint pacing (MPP) of the LV has been shown to improve
the acute hemodynamic response.
OBJECTIVE The purpose of this study was to test the hypothesis
that patients treated with MPP in whom LV pacing location is
optimized have better long-term clinical outcomes than do patients
treated with conventional CRT.
METHODS We evaluated the echocardiographic and clinical
response of 110 patients with HF treated for nearly 1 year with
either conventional CRT (standard [STD] group, n ¼ 54, 49%), CRT
with hemodynamic and electrical optimization of the LV pacing site
(optimized [OPT] group, n ¼ 36, 33%), or OPT combined with MPP
(OPT þ MPP group, n ¼ 20, 18%). Responders were classiﬁed in
terms of reduction in end-systolic volume index ≥15%, reduction in
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1547-5271/$-see front matter B 2016 The Authors. Published by Elsevier Inc. on
10.1016/j.hrthm.2016.05.015variation (NYHA response with no HF-related hospitalization events
or death).
RESULTS In STD, OPT, and OPT þ MPP groups, 56%, 72%, and 90%
of patients, respectively, were end-systolic volume index responders
(P ¼ .004) and 67%, 78%, and 95% were NYHA class responders
(P¼ .012); 59%, 67%, and 90% of patients exhibited a 1-year Packer
score of 0 (P ¼ .018). These trends remained signiﬁcant after
adjustment for confounding factors by multivariate logistic analysis.
CONCLUSION Combining MPP with optimal positioning of the LV
lead on the basis of electrical delay and hemodynamics enhances
reverse remodeling and improves clinical outcomes beyond the
effect due to conventional CRT.
KEYWORDS Heart failure; Cardiac resynchronization therapy;
Multipoint pacing; Hemodynamic response; Left ventricular
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by Elsevier Inc. on behalf of Heart Rhythm Society. All rights reserved.Introduction
Cardiac resynchronization therapy (CRT) involves electrical
stimulation of the left ventricle (LV) of patients with heart
failure (HF). Commonly applied through a tributary of the
coronary sinus, it attempts to restore ventricular synchrony
and improve hemodynamics. CRT has been shown to reduceHF-related morbidity and mortality and to improve quality of
life.1–3 However, in approximately one-third of the patients
with HF, CRT fails to improve clinical parameters, and in up
to 50% of the treated patients it does not reverse LV
remodeling (decrease in LV end-systolic volume [ESV]).4,5
Efforts to address CRT nonresponse have included
optimizing the LV pacing site. While attempts have been
made to identify superior LV pacing sites on the basis of
anatomy alone, but consistent correlations with CRT
response have not emerged across patient populations.6
Addressing electrical dyssynchrony directly by pacing at
the latest activated LV site, however, seems promising.
Previous studies,7,8 including ours,9 have demonstrated a
correlation between the intrinsic electrical delay of an LVbehalf of Heart Rhythm Society. All rights reserved. http://dx.doi.org/
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and reduction in electrical dyssynchrony. Speciﬁcally, pos-
itive correlations have emerged between Q-LV (LV lead
electrical delay) and both LV dP/dtmax (maximum rate of
increase in LV pressure) and QRS narrowing.9 Moreover,
pacing at sites with longer Q-LV is linked to better long-term
outcome.7,10,11
The recently introduced quadripolar leads simplify pacing
site selection by allowing the LV pacing site along a target
vein to be remotely programmed without lead repositioning.
Additional acute hemodynamic improvement has been
achieved with the introduction of multipoint pacing (MPP)
of the LV,12–17 whereby multiple LV sites along the single
quadripolar lead are stimulated in order to capture a broader
region of excitable myocardium.18 It has been demonstrated
that MPP elicits a greater hemodynamic improvement than
does conventional CRT (pacing single sites at the right
ventricular [RV] and the LV lead) in terms of LV
dP/dtmax,
12,13 pressure-volume loop metrics,14 LV radial
strain,15 LV outﬂow tract velocity-time integral,16 and impedance
cardiography.17
However, little information is available on the long-term
beneﬁts of MPP and there is conﬂicting evidence as to
whether the acute hemodynamic response to CRT predicts
long-term clinical outcome.19,20 We therefore aimed to
investigate the long-term effects of optimized LV lead
placement, both alone and in combination with MPP. To
this end, we analyzed the 1-year follow-up data on patients
treated in our hospital and compared echocardiographic and
clinical improvements in 3 patient groups: those undergoing
conventional CRT, those with optimized lead placement
(lead at the longest Q-LV), and those in whom optimized
lead placement was combined with MPP.Methods
Study design
This investigation was a retrospective single-center study
involving nonparallel cohorts. The study protocol was
approved by the local ethics committee and adhered to the
principles outlined in the Declaration of Helsinki. All
patients enrolled in the study were indicated for CRT in
accordance with the European Society of Cardiology/Euro-
pean Heart Rhythm Association guidelines21 and provided
written informed consent to use their clinical data.
The following baseline demographic characteristics,
comorbidities, and HF status metrics were recorded before
CRT implantation: age, sex, New York Heart Association
(NYHA) class, LV ejection fraction, end-diastolic volume
index (EDVi), end-systolic volume index (ESVi), QRS
duration, and history of ischemic cardiomyopathy, left
bundle branch block, percutaneous coronary intervention
(PCI), coronary artery bypass graft, valvular disease, acute
myocardial infarction, diabetes, hypertension, atrial ﬁbrillation,
and renal failure (glomerular ﬁltration rate o30 mL/min).
EDVi and ESVi were calculated as the ratio of EDV and
ESV to body surface area, respectively. Echocardiographicparameters and inter- and intraobserver variability in our center
have already been described.22
QRS morphology was classiﬁed according to American
Heart Association/American College of Cardiology Founda-
tion/Heart Rhythm Society guidelines.23 Because all these
measurements had been taken as part of standard clinical care
in our center and before the study groups were formed, the
researchers performing the analyses were blinded to the
group to which a patient belonged.
In accordance with our standard implantation procedure,
the RV lead was implanted in the mid-septum and the atrial
lead was implanted in the right atrial appendage. A pre-
viously described telescopic approach24 was used for can-
nulation of the coronary sinus and subcannulation of all
suitable collateral veins; this approach allows continuous
selective navigation with angiographic visualization. All
veins that were actually cannulated and then targeted with
the LV pacing lead were deﬁned as available veins. We did
not collect data on veins that were visualized but not
cannulated. LV pacing sites were anatomically classiﬁed
by using a system previously established by Singh et al.25
Brieﬂy, on segmenting the left anterior oblique (short-axis)
ﬂuoroscopic view, the pacing site was classiﬁed as anterior,
anterolateral, lateral, posterolateral, or posterior; on segment-
ing the right anterior oblique (long-axis) ﬂuoroscopic view,
the pacing site was classiﬁed as basal, mid, or apical.
After nearly 1 year of follow-up, patients were reeval-
uated to determine the chronic response to resynchronization
therapy; ESVi, NYHA class, and Packer score26 were
compared with the preimplantation baseline values. “ESVi
responders” were those with a reduction in ESVi of ≥15%27;
“NYHA responders” were those with a reduction in NYHA
class of ≥1; and “Packer responders” were those exhibiting a
Packer score of 0, indicating a reduction in NYHA class with
no HF-related hospitalization events or death in the year
before the follow-up examination.Cohort description
Three groups of patients were compared.
The conventional CRT group was composed of 54
consecutive patients with HF with conventional CRT devices
equipped with bipolar LV leads without any optimization
(standard [STD] group). The STD group received CRT
treatment between January 2011 and March 2012. According
to our practice,24 coronary sinus angiography was performed
to visualize a target vein in the LV free wall, preferably in the
lateral or posterolateral region. The target vein was chosen
according to the angle, bifurcation, and caliber of the vessel;
the anatomical position along the LV free wall (for lead
stability); and the electrical parameters (pacing threshold and
phrenic nerve stimulation).
The second CRT group was composed of 36 patients with
HF with CRT devices equipped with either bipolar or
quadripolar LV leads, the sites of which were optimized on
the basis of LV dP/dtmax and Q-LV (optimized [OPT]
group). OPT group patients underwent implantation between
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were subcannulated using an angiographic telescopic
approach to selectively visualize all suitable collateral veins,
as described in our previous study.9 At each pacing site,
classiﬁed in accordance with the criterion used by Singh
et al,25 QRS duration and electrical delay (Q-LV) were
measured using a BARD LabSystem Pro EP V2.4a recording
system (C.R. Bard Inc, Lowell, MA). The Q-LV interval was
deﬁned as the interval from the onset of the intrinsic QRS on
the surface electrocardiogram to the ﬁrst large positive or
negative peak of the LV electrogram, recorded in bipolar
conﬁguration. Measurements of LV dP/dtmax were taken
with a Certus Pressure Wire and PhysioMon software (St.
Jude Medical Systems AB, Uppsala, Sweden). The LV lead
was left at the pacing site corresponding to the greatest
increase in LV dP/dtmax (also corresponding to the latest
activated site, as previously reported9).
The third group was composed of 20 patients. After the
same acute optimization procedure described for the OPT
group, these patients received CRT devices equipped with
quadripolar LV pacing leads capable of delivering MPP
therapy (Quadra Assura MP CRT-D with the Quartet lead,
St. Jude Medical, Sylmar, CA) (OPTþMPP group). OPTþ
MPP group patients underwent implantation between July
2013 and October 2014.
In all patients, CRT devices were programmed with a ﬁxed
atrioventricular delay of 130 ms. In STD and OPT groups,
simultaneous interventricular RV-LV pacing was programmed.
CRT devices in the OPTþMPP group were programmed with
5 ms (minimum value available) intraventricular LV1-LV2
pacing and 5 ms (minimum value available) interventricular
LV2-RV pacing. The ﬁrst vector (LV1) was selected according
to the last electrically activated site.Statistical analysis
To compare characteristics between patient groups (STD,
OPT, and OPT þ MPP) at the baseline and follow-up
examination, the Pearson χ2 test was used for categorical
parameters, while 1-way analysis of variance was used for
continuous parameters. The Bonferroni post hoc method was
used for descriptors with different distribution between
patient groups.
The χ2 test was used for the intergroup comparison of the
proportions of the responses considered (ESVi, NYHA class,
and Packer score); values are presented with their 95%
conﬁdence intervals (Wilson’s calculation method).28
A linear-by-linear association test for trend was also
carried out.
Potential confounders (male sex, age, left bundle branch
block, atrial ﬁbrillation, CRT with deﬁbrillator, ischemic
cardiomyopathy, acute myocardial infarction, percutaneous
coronary intervention-coronary artery bypass grafting (PCI-
CABG), valvulopathy, hypertension, glomerular ﬁltration
rate o30 mL/min, diabetes, oral anticoagulation therapy,
antiarrhythmic therapy, basal ESVi, and basal NYHA class)
were selected using the Wald’s forward stepwise method andwere included as covariates in 3 multivariate logistic
regression models, together with the type of pacing imple-
mented (with STD pacing as reference) and the response
considered (ESVi or NYHA class or Packer score) as
dependent variables. Interactions between the factors
included were tested. Adjusted odds ratios (ORs) for each
factor and their 95% conﬁdence intervals, correct classiﬁca-
tion proportions, and χ2 statistics for the ﬁnal models were
calculated. In the logistic regression models, a probability
level to enter the models was ﬁxed at Po.10.
All calculations were performed using SPSS version 22.0
(IBM Corp, Armonk, NY).Results
Study population
Preimplantation baseline patient demographic characteris-
tics, comorbidities, and HF metrics in all 3 groups were
similar overall, except for age, which was signiﬁcantly
higher in the OPT group (Bonferroni test for post hoc
comparison: OPT vs STD, P ¼ .01; OPT vs OPT þ MPP,
P ¼ .005) (Table 1).
The anatomical distribution of LV leads in each group is
illustrated in Figure 1. No signiﬁcant differences were found
between the 3 groups. LV leads were predominantly placed
in mid-to-apical sites along veins in the lateral LV wall, but
there were more posterolateral lead placements in the STD
group.
We collected data from echocardiography images looking
for the akinetic/dyskinetic regions. In particular, an anterior/
anteroseptal akinetic/dyskinetc region was present in 18.5%,
16.6%, and 10% of patients in STD, OPT, and OPT þ MPP
groups, respectively. A posterior akinetic/dyskinetic region
was present in 11.1%, 25%, and 20% of patients in STD,
OPT, and OPT þ MPP groups, respectively. A lateral
akinetic/dyskinetic region was present in 7.4%, 13.8%, and
10% of patients in STD, OPT, and OPT þ MPP groups,
respectively. No signiﬁcant differences in the distribution of
akinetic/dyskinetic areas were found in the 3 groups. A total
of 3.0 ± 0.8 and 3.1 ± 0.6 veins per patient were cannulated
in OPT and OPT þ MPP groups, respectively, while the
mean number of veins not suitable for cannulation was 0.26
± 0.35 and 0.27 ± 0.43 veins per patient (small size or
extreme tortuosity) in OPT and OPT þ MPP groups,
respectively.
In OPT and OPT þ MPP groups, the lead was placed at
the longest Q-LV site, with the exception of 1 case (a patient
of the OPT group), in whom the lead was slightly pulled
back to a mid position owing to the high phrenic nerve
stimulation pacing threshold in the lateral-apical position. At
this site, the Q-LV and the increase in LV dP/dtmax were the
second highest values of the sets.Chronic CRT response
Follow-up evaluations of the response to CRT were performed
in STD, OPT, and OPTþMPP groups approximately 300 days
Table 1 Baseline patient characteristics.
STD (n ¼ 54, 49%) OPT (n ¼ 36, 33%) OPT þ MPP (n ¼ 20, 18%) p
Age (years, mean±SD) 69.7 ± 10.4 76.1 ± 6.5 67.4 ± 12.5 0.002
Male Gender (%) 37 (68.5) 24 (66.7) 16 (80.0) 0.549
LBBB (%) 33 (61.1) 22 (61.1) 13 (65.0) 0.95
AF (%) 15 (27.8) 13 (36.1) 8 (40.0) 0.530
ICMP (%) 27 (50.0) 20 (55.6) 11 (55.0) 0.853
AMI (%) 18 (33.3) 17 (47.2) 6 (30.0) 0.311
PCI-CABG (%) 18 (33.3) 14 (38.9) 7 (35.0) 0.863
Valvulopathy (%) 9 (16.7) 8 (22.2) 2 (10.0) 0.143
Hypertension (%) 43 (79.6) 32 (88.9) 15 (75.0) 0.366
Creatinine (ml, mean±SD) 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 0.826
GFR o 30.0 (mL/min) 8 (14.8) 3 (8.3) 1 (5.0) 0.404
Diabetes (%) 19 (35.2) 8 (22.2) 5 (25.0) 0.376
Insulin therapy (%) 7 (13.0) 5 (13.9) 1 (5.0) 0.575
OAT (%) 17 (31.5) 16 (44.4) 9 (45.0) 0.364
Primary prevention (%) 10 (18.5) 5 (13.9) 1 ( 5.0) 0.339
Optimized medical therapy (%) 39 (72.2) 29 (80.6) 16 (80.0) 0.603
LVEF (%, mean±SD) 30.4 ± 6.3 31.1 ± 6.3 27.2 ± 4.3 0.054
ESVi (ml/m2, mean ± SD) 76.6 ± 25.4 70.7 ± 27.7 72.9 ± 28.2 0.572
NYHA class (%)
I 1 (1.9) 0 0 0.700
II 11 (20.4) 5 (13.9) 3 (15.0)
III 37 (68.5) 30 (83.3) 16 (80.0)
IV 5 (9.3) 1 (2.8) 1 (5.0)
AF ¼ atrial ﬁbrillation; AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass graft; CRT ¼ cardiac resynchronization therapy; ESVi ¼ end-
systolic volume index; GFR ¼ glomerular ﬁltration rate; ICMP ¼ ischemic cardiomyopathy; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection
fraction; MPP ¼ MultiPoint Pacing; NYHA ¼ New York Heart Association; OAT ¼ oral anticoagulant therapy; OPT ¼ CRT with optimized left ventricular site;
PCI ¼ percutaneous coronary intervention; SD ¼ standard deviation; STD ¼ standard.
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NYHA class, NYHA class variation, and number of events
including all-cause death or HF hospitalization) are summarized
in Table 2.
The response rates in terms of ESVi, NYHA class, and
Packer score are listed in Table 3 and presented in Figure 2.
In terms of a ≥15% reduction in ESVi relative to
preimplantation baseline values, 55.6% (30 of 54) of patients
in the STD group, 72.2% (26 of 36) in the OPT group, and
90.0% (18 of 20) in the MPP þ OPT group were considered
as responders.Figure 1 Anatomical distribution of LV leads. Distribution of lead location am
group. LV ¼ left ventricular; MPP ¼ multipoint pacing; OPT ¼ optimized; RV ¼In terms of a reduction in NYHA class, 66.7% (36 of 54)
of patients in the STD group, 77.8% (28 of 36) in the OPT
group, and 95% (19 of 20) in the MPP þ OPT group were
considered responders. The NYHA class improvement in
each group is shown in Figure 3.
Interestingly, 35% (7 of 20) of patients in the MPPþOPT
group showed an NYHA class downgrade of 2 or more
classes as compared with only 20.4% (11 of 54) of patients in
the STD group and 11.1% (4 of 36) of patients in the OPT
group. Similarly, more patients in the MPP þ OPT group
than in the STD and OPT groups were Packer scoreong the 15 LV wall segments, shown as the percentage of patients in each
right ventricle; STD ¼ standard.
Table 2 Patient characteristics at 1-year follow-up.
STD (n ¼ 54) OPT (n ¼ 36) OPT þ MPP (n ¼ 20) P
Follow-up (days, mean ± SD) 317.7 ± 99.8 300.6 ± 96.9 281.3 ± 97.5 0.349
ESVi (ml/m2, mean ± SD) 61.4 ± 26.8 53.3 ± 25.1 59.1 ± 27.1 0.357
NYHA class (%)
I 12 (22.2) 6 (16.7) 14 (25.0) 0.182
II 33 (61.1) 25 (69.4) 37 (66.1)
III 9 (16.7) 4 (11.1) 4 (7.1)
IV 0 (0) 1 (2.8) 1 (1.8)
NYHA class delta (%)
0 18 (33.3) 8 (22.2) 1 (5.0) 0.046
-I 25 (46.3) 24 (66.7) 12 (60.0)
-II 9 (16.7) 4 (11.1) 7 (35.0)
-III 2 (3.7) 0 0
Events (%)† 5 (9.3) 7 (19.4) 1 (5.0) 0.198
CRT ¼ cardiac resynchronization therapy; ESVi ¼ end-systolic volume index; LV ¼ left ventricle; MPP ¼ MultiPoint Pacing; NYHA ¼ New York Heart
Association; OPT ¼ CRT with optimized LV site; SD ¼ standard deviation; STD ¼ standard CRT.
†Events: number of events in the follow-up period (all-cause death or hospitalization due to HF worsening).
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patients experienced a reduction in NYHA class with no
1-year HF-related hospitalization or death (Packer score 0) as
compared with 59.3% (32 of 54) of patients in the STD
group and 66.7% (24 of 36) of patients in the OPT group.
We collected data on pacing history during follow-up, and
in particular pacing percentage, premature ventricular con-
traction, and atrial ﬁbrillation burden did not signiﬁcantly
differ between groups. Moreover, the compliance with drug
therapy between groups did not vary signiﬁcantly.
Multivariate analysis
Each of the responses considered, ESVi, NYHA class, and
Packer score, was included as a dependent variable in 3
distinct multivariate logistic regression models.
As shown in Table 4, OPT þMPP was a strong predictor
of ESVi response vs STD pacing (OR 9.53; P ¼ .007),
whereas no difference was found between OPT and STD
pacing (OR 2.16; P ¼ .118). Two other factors were
signiﬁcantly associated with ESVi response: the favorable
presence of hypertension (OR 3.03; P ¼ .048) and the
unfavorable effect of PCI-coronary artery bypass graft (OR
0.33; P ¼ .016).
With regard to NYHA response, OPTþMPP displayed a
strong independent effect vs STD pacing (OR 9.59; P ¼
.044), whereas no difference was found between OPT andTable 3 CRT Response Rates.
STD (54) (%; 95% CI) OPT (36) (%; 9
ESVi response 30 (55.6%; 42.4-68.0) 26 (72.2%; 56
NYHA response 36 (66.7%; 53.4-77.8) 28 (77.8%; 61
PACKER’s response 32 (59.3%; 46.0-71.3) 24 (66.7%; 50
CI¼ conﬁdence intervals; CRT ¼ cardiac resynchronization therapy; ESVi ¼
NYHA ¼ New York Heart Association; OPT ¼ optimized; STD ¼ standard.
†X2¼ Pearson chi-square.STD pacing (OR 1.38; P ¼ .568). Two other factors were
signiﬁcantly associated with NYHA response: the baseline
NYHA class (OR 8.83; P ¼ .001; in that we most frequently
observed a decrease in NYHA class in the more severe cases)
and the unfavorable effect of the presence of severe renal
insufﬁciency (OR 0.18; P ¼ .024).
An independent effect on Packer’s response was exerted
by OPT þ MPP vs STD pacing (OR 7.95; P ¼ .064),
whereas no difference was found between OPT and STD
pacing (OR 1.20; P ¼ .742). Two other factors were
signiﬁcantly associated with Packer’s response: the baseline
NYHA class (OR 9.64; P¼ .001) and the unfavorable strong
effect of the presence of severe renal insufﬁciency (OR 0.01;
P ¼ .001).
No signiﬁcant interactions were found between factors
included in the models.
Discussion
Our retrospective single-center study is the ﬁrst to demon-
strate that the combination of OPT and MPP improves long-
term outcome of CRT to levels of around 90%. In the STD
group, the percentage of responders (56% volumetric res-
ponders and 67% NYHA class responders) was well within
the range indicated in a large number of studies, which
reported a lack of clinical response in approximately 30% of
patients and a lack of structural remodeling response in5% CI) OPT þ MPP (20) (%; 95% CI) P
.0-84.2) 18 (90%; 69.9-97.2) X2 ¼ 0.015†
LT ¼ 0.004
.9-88.3) 19 (95.0%; 76.4-99.1) X2 ¼ 0.039†
LT ¼ 0.012
.3-79.8) 18 (90.0%; 69.9-97.2) X2 ¼ 0.043†
LT ¼ 0.018
end-systolic volume index; LT¼ Linear trend; MPP ¼ multipoint pacing;
Figure 2 ΔESVi, ΔNYHA, and Packer’s response rates. Response
indicates ΔESVi ≥15%, ΔNYHA class 40, or Packer score 0 at follow-
up relative to preimplantation baseline values. The vertical segments
represent the 95% conﬁdence intervals of the estimated proportions. ESVi
¼ end-systolic volume index; MPP ¼ multipoint pacing; NYHA ¼ New
York Heart Association; OPT ¼ optimized; STD ¼ standard.
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tended to improve this response, the increase was not
signiﬁcant in this relatively small population. However,
implementing MPP at optimized LV pacing sites resulted
in an adjunctive effect, with an increase in response rates to
90% for ESVi, 95% for NYHA class improvement, and 90%
for Packer score.
These data extend earlier observations that OPT and MPP
acutely improve both the electrical and the hemodynamic
response. Our group linked electrical delay with acute
hemodynamic evaluation9 and found a signiﬁcant correlation
between increased LV dP/dtmax and Q-LV in 32 patients. In
that study, the correlation was observed in every vein, with
an average of 6.4 ± 2.3 pacing sites in each patient.
Recent research has characterized the acute hemodynamic
advantages of MPP over conventional biventricular pacing
by using a variety of systolic and diastolic metrics.13–15 Our
previous study revealed an acute, intrapatient, hemodynamic
superiority of MPP over conventional CRT across multiple
veins and LV pacing sites in 90% (26 of 29) of patients.12
With regard to long-term outcome, optimal positioning of
the LV pacing lead, based on the latest electrical delay, hasFigure 3 Reduction in NYHA class (NYHA class at follow-up minus baselin
improvement in NYHA class. MPP ¼ multipoint pacing; NYHA ¼ New York Hshown a strong and independent association with reverse
remodeling and quality of life8,11 and with reduced hospital-
ization and improved survival.7,10 In the present study, the
difference between STD and OPT was not signiﬁcant; this
was probably due to the much smaller sample size than that
used in the aforementioned studies.
However, the combination of OPT and MPP did signiﬁ-
cantly improve long-term CRT response.
In the present study, the mode of MPP applied was dual
bipolar pacing (combining bipolar pacing of the 2 proximal
and 2 distal electrodes on the lead). No attempts were made
to optimize atrioventricular, interventricular, or intraventric-
ular delay. While several studies have shown the acute
hemodynamic beneﬁt of optimizing these delays, evidence
that such optimization improves long-term response is
scarce.29,30
Other MPP-focused studies have reported that the intra-
ventricular LV-LV delay between the 2 MPP LV pacing
vectors may also impact on acute hemodynamics.14
Pappone et al31 compared the 1-year responses of 44
patients randomized (in a 1:1 ratio) to either MPP or
conventional CRT after acute hemodynamic optimization
of not only the LV pacing site but also the interventricular
RV-LV delay and, in patients treated with MPP, the intra-
ventricular LV-LV delay. Optimal LV pacing sites were
chosen from among the electrodes of a quadripolar lead at a
ﬁxed position. Pacing vectors were optimized individually
on the basis of LV dP/dtmax measurements. One-year
response rates were reported in terms of a 15% reduction
in ESV (76%MPP vs 57% conventional CRT) and improve-
ment in NYHA class (90%MPP vs 84% conventional CRT).
The effect size in their study seems smaller than that in our
study, supporting the importance of optimizing the lead
positioning by exploring different options rather than only a
single vein.
Interestingly, in the present study, the distribution of LV
lead location was similar across all 3 groups, regardless of
whether the position was guided by the electrical delay and,
despite potential minor changes in the implantation practice
over time, ultimately there were no signiﬁcant differences in
the distribution of the location of the LV lead between the
groups. In other words, the pacing site that provided optimal
hemodynamics was patient-speciﬁc and not associated withe NYHA class). The black slice indicates patients who did not show any
eart Association; OPT ¼ optimized; STD ¼ standard.
Table 4 Multivariate analysis showing independent predictors of ESVi response, NYHA response and Packer’s response.
Logistic regression dependent variable: ESVi response
Correct Classiﬁcation¼ 69.1%, Chi-square¼19.1, df¼4, p¼0.001
95% C.I. for OR
Factors OR Lower Upper p
CRT: OPT vs STD 2.16 0.82 5.70 0.118
OPT þ MPP vs STD 9.53 1.84 49.27 0.007
Hypertension 3.03 1.01 9.10 0.048
PCI-CABG 0.33 0.13 0.81 0.016
Logistic regression dependent variable: NYHA response
Correct Classiﬁcation¼ 81.8%, Chi-square¼30.3,df¼4, p¼0.0001
95% C.I. for OR
Factors OR Lower Upper p
CRT: OPT vs STD 1.38 0.45 4.23 0.568
OPT þ MPP vs STD 9.59 1.06 86.69 0.044
NYHA pre 8.83 2.93 26.61 0.001
GFRo30 0.18 0.04 0.80 0.024
Logistic regression dependent variable: PACKER’s response
Correct Classiﬁcation¼ 80.1%, Chi-square¼49.6,df¼4, p¼0.001
Factors OR
95% C.I. for OR
pLower Upper
CRT: OPT vs STD 1.20 0.39 3.75 0.742
OPT þ MPP vs STD 7.95 0.88 71.58 0.064
NYHA pre 9.64 2.98 31.23 0.001
GFRo30 0.01 0.001 0.13 0.001
CABG ¼ coronary artery bypass graft; CI ¼ conﬁdence intervals; CRT ¼ cardiac resynchronization therapy; ESVi ¼ end-systolic volume index; GFR ¼
glomerular ﬁltration rate; MPP¼ multipoint pacing; NYHA ¼ New York Heart Association; OPT ¼ optimized; OR¼ odds ratio; PCI ¼ percutaneous coronary
intervention; STD ¼ standard.
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This ﬁnding is consistent with the difﬁculty of identifying
superior LV pacing sites on the basis of anatomical criteria
alone, as experienced in previous studies,9 and supports the
notion that LV lead positioning needs to be optimized
individually.Study limitations
This study was limited to a single center in order to maintain
consistency in terms of lead placement and data collection.
As a consequence, the patient sample size was limited,
although comparable to that of previous MPP studies. As we
had observed the acute clinical beneﬁts of MPP in our
previous study,11 we chose not to withhold MPP therapy for
the sake of randomizing patients. Although patients were not
randomized to each group, none of the baseline character-
istics that differed among the study groups were ultimatelyidentiﬁed as potential predictors of response rate. Moreover,
the distribution of LV lead location was similar between
groups, strengthening the concept of a patient-speciﬁc best
position. But this concept also needs to be conﬁrmed in a
randomized clinical trial. Another limitation could be the
inclusion of patients in different periods of time. This was the
result of a change in our implantation procedure from a
conventional to an optimized approach. However, indica-
tions for CRT in our clinical practice did not change in this
period, as demonstrated by the absence of signiﬁcant differ-
ences in 3 groups.
Another potential limitation is the lack of information of
scar burden because magnetic resonance imaging examina-
tion was not part of the preimplantation screening in all 3
groups.
In light of the inherent limitations of this study, its
implications should be conﬁrmed in a larger, randomized,
prospective, multicenter study.
1651Zanon et al Long-Term Beneﬁt of Optimized Multipoint CRTConclusion
The results of this follow-up study demonstrate the long-term
superiority of LV site optimization plus MPP over conven-
tional CRT. Combining MPP with acute optimization, both
electrical and hemodynamic, was found to be able to reverse
the long-term progression of HF and to improve clinical
outcomes, resulting in response rates of around 90%.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrthm.
2016.05.015.References
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